PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders

Latest News Updates

10th Closed Scientific Expert Meeting of the Editorial Board

25th May 2019, Maastricht, The Netherlands (Educational supporters)

Hepatic lipid metabolism: Storage vs secretion

Hepatic lipid metabolism: Storage vs secretion

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Jan Boren

Posted on 8 August 2019 | Posted by Jan Boren | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins

Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Brian Ference

Posted on 24 July 2019 | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations

New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Erik Stroes

Posted on 24 July 2019 | Posted by Erik Stroes | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

Inclisiran: The Phase 3 trial

Inclisiran: The Phase 3 trial

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Frederick Raal

Posted on 24 July 2019 | Posted by Frederick J. Raal | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

FOURIER trial: Update on subgroup analyses

FOURIER trial: Update on subgroup analyses

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Peter Sever

Posted on 24 July 2019 | Posted by Peter Sever | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

ODYSSEY OUTCOMES: Update

ODYSSEY OUTCOMES: Update

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Andreas M Zeiher

Posted on 23 July 2019 | Posted by Andreas M Zeiher | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

The new AHA/ACC Treatment Guidelines: Critical appraisal

The new AHA/ACC Treatment Guidelines: Critical appraisal

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Henry Ginsberg

Posted on 17 July 2019 | Posted by Henry Ginsberg | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?

Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Børge Nordestgaard

Posted on 17 July 2019 | Posted by Børge Nordestgaard | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved